Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

NCT06311214

Status	RECRUITING
Phase	Phase 2
Sponsor	National Cancer Institute (NCI)
Enrollment	500 participants

Key Eligibility Criteria

Inclusion (47)

- Patients must have histologically confirmed solid tumor requiring therapy and meet one of the following criteria:
- Patients must have disease not amenable to curative-intent therapy AND
- Patients who have had disease progression after treatment with all available therapies for their disease that are known to confer benefit or are intolerant to such treatment will be eligible, if other eligibility criteria are met. If the patient is currently receiving therapy without progression, the clinician must have assessed that the current therapy is no longer benefitting the patient, or that the patient is not tolerating the therapy. Patients can be screened on ADC MATCH if they have had three or fewer-lines of chemotherapy in the advanced/metastatic setting and are expected to need a treatment change within 6 months, and ADC MATCH is felt to be appropriate next line therapy AND
- Patients with disease for which no standard treatment exists that has been shown to confer benefit OR
- Patients who are willing to forego standard therapies known to confer benefit

... and 42 more (see full listing online)

Exclusion (37)

- Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease. Patients with treated brain metastases are eligible if follow-up brain imaging 4 weeks after central nervous system-directed therapy shows no evidence of progression
- Clinically significant cardiovascular condition including: (1) history of congestive heart failure (New York Health Association class \> 2), (2) any history of unstable angina, (3) myocardial infraction within the past 12 months, or (4) any history of supraventricular arrhythmia or ventricular arrhythmia requiring treatment or intervention within the past 12 months
- History or presence of abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful
- Active or chronic corneal disorder including, but not limited to, Sjogren's syndrome, Fuchs corneal dystrophy (requiring treatment), history of corneal transplantation, active herpetic keratitis, and/or active ocular conditions requiring ongoing treatment/monitoring such as wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, presence of papilledema, and acquired monocular vision
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to the ADCs used in the study

... and 32 more (see full listing online)

Locations (27 total)

City of Hope Comprehensive Cancer Center, Duarte, California, United States
UC San Diego Health System - Encinitas, Encinitas, California, United States
City of Hope at Irvine Lennar, Irvine, California, United States
... and 24 more locations